Orphalan
Orphalan is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Orphalan.
Orphalan is a company.
Key people at Orphalan.
Key people at Orphalan.
Orphalan is a privately owned international biopharmaceutical company founded in 2011, specializing in the development and commercialization of orphan drugs for rare diseases.[1][2][3] Its flagship product, Cuvrior® (trientine tetrahydrochloride, also branded as Cuprior® in Europe and other regions), treats Wilson's disease—a rare genetic disorder causing toxic copper accumulation—offering a best-in-class alternative to existing therapies with fewer side effects and easier handling, such as room-temperature stability.[1][3][4] Orphalan serves patients worldwide, particularly those with rare neurological, oncological, and pediatric conditions, addressing unmet needs through a patient-centered approach that emphasizes accessibility, global commercialization, and partnerships with healthcare professionals and nonprofits.[1][4] The company has achieved regulatory approvals in over 38 countries, including FDA approval in 2022 and China NMPA in 2024, with marketing in 28+ countries, bolstered by its recent December 2025 acquisition of Orphelia Pharma to expand into pediatric neurology and oncology.[1][3][4]
Orphalan was founded in 2011 in Paris, France, emerging from a collaboration between AGEPS (a French hospital pharmacy group) and Hôpital Lariboisière to reposition existing drugs for orphan diseases by leveraging untapped academic research and clinical data.[1][3] The company's initial focus was Wilson's disease, where current treatments like penicillamine had limitations such as side effects and refrigeration needs; Orphalan developed trientine tetrahydrochloride as a superior option.[3] Early traction came from launching Cuprior® in Europe in 2015, supported by Advent Life Sciences as the sole Series A investor in 2015.[3][4] Leadership evolved with Dr. Naseem Amin becoming CEO in June 2017; his background includes roles at Arix Bioscience, Advent Life Sciences, Smith & Nephew, Biogen Idec, Genzyme, and Baxter, bringing expertise in life sciences R&D, business development, and venture capital.[2] Pivotal moments include FDA approval of Cuvrior™ in 2022, China approval in 2024, and the 2025 Orphelia Pharma acquisition, solidifying its global footprint.[1][3]
Orphalan rides the orphan drug trend, where market forces favor high-margin therapies for rare diseases due to regulatory incentives like Orphan Drug Designation, expedited approvals, and 7-10 year market exclusivity, amid a global rise in diagnosed rare conditions.[1][2][3] Timing is ideal post-2020s biotech boom, with growing emphasis on precision medicine and gene-related disorders like Wilson's disease (affecting 1 in 30,000).[3] Favorable dynamics include untapped emerging markets (e.g., China approval) and partnerships addressing access gaps in developing countries, countering traditional pharma's neglect of low-volume diseases.[1][4][5] Orphalan influences the ecosystem by pioneering drug repositioning, accelerating therapies via academic collaborations, and expanding via M&A like Orphelia, setting a model for agile biopharma players in Europe's rare disease space.[1][3]
Orphalan's momentum—fueled by Cuvrior®'s global rollout, recent acquisition, and patent portfolio—positions it for accelerated growth in orphan drugs, potentially targeting 50+ countries and new indications in pediatric oncology/neurology.[1][2][3] Trends like AI-driven drug discovery, expanded orphan incentives, and rising rare disease awareness will shape its path, enabling pipeline diversification beyond Wilson's.[3][5] Its influence may evolve from niche player to European rare disease leader with global scale, prioritizing underserved patients; watch for further M&A or partnerships to sustain innovation in this high-need, high-reward sector. This builds on its core mission: transforming rare disease care through accessible, innovative therapies.[1][4]
